A number of therapies are available to treat mild-moderate COVID-19 on an outpatient basis. If you are feeling sick from COVID-19, visit a Baptist Health Urgent Care or Baptist Health Urgent Care Express for a medical evaluation to see if one of these therapies is right for you.
Currently, the FDA has granted emergency use authorization for two oral therapies for treatment of COVID-19: nirmatrelvir/ritonavir (Paxlovid®, from Pfizer) and molnupiravir (Lagevrio®, from Merck).
Both of these medications require a prescription from a licensed practitioner. Paxlovid is the best current therapy for high-risk outpatients with mild-moderate COVID-19, even better than the monoclonal antibody bebtelovimab.
Yes. Patients who are feeling sick from COVID-19 can visit Baptist Health Urgent Care or Baptist Health Urgent Care Express for a medical evaluation to see if they qualify for one of these medications.
Yes for both. For patients looking to fill a Paxlovid or molnupiravir prescription, several Baptist Health retail pharmacies carry these products, and their information listed below.
For the health and safety of staff and other patients, COVID-19 positive patients should not enter Baptist Health pharmacies. We can arrange pick-up of the medications with a family member or we can also offer curbside pickup or home delivery. Prescribers are able to electronically send prescriptions to Baptist Health pharmacies.
Please take note of hours of operation. Prescriptions received by 3 PM ET on weekdays are eligible for same day delivery.
There are several different types of monoclonal antibody products.
Each antibody product targets specific variants and sub-variants of the COVID-19 virus.
Under the FDA’s EUA, we can use monoclonal antibody products that target the dominant strain in our area. The dominant strain in Florida as of early June 2022 is Omicron sub-variant BA.2.12.1
Bebtelovimab (from Eli Lilly) is currently authorized by an FDA EUAfor the treatment of mild-moderate COVID-19, including infection caused by Omicron sub-variant BA.2.12.1.
Tixagevimab/cilgavimab (Evusheld from AstraZenica) is currently authorized by an FDA EUA for pre-exposure prophylaxis (prevention) of COVID-19, including infection caused by Omicron sub-variant BA.2.12.1.
Previous SARS-CoV-2 monoclonal antibody products including bamlanivimab/etesevimab (from Eli Lilly), casirivimab/imdevimab (REGEN-COV from Regeneron), and sotrovimab (Xevudy from GlaxoSmithKline) are no longer authorized for use in the United States due to lack of adequate activity against Omicron and Omicron sub-variants.
Baptist Health Urgent Care Centers can refer patients to our facilities to receive bebtelovimab (from Eli Lilly), when clinically appropriate. Bebtelovimab may be an option for patients that cannot take Paxlovid. Bebtelovimab has an FDA Emergency Use Authorization for treatment of mild-moderate COVID-19 in high-risk outpatients. It is active against currently circulating predominant SARS-CoV-2 variants.
It is important to note that while injectable monoclonal antibodies were once the preferred treatment of outpatient mild-moderate COVID-19 for high-risk patients, currently oral Paxlovid is the best treatment option.
Patients must be evaluated by a medical professional at a Baptist Health Urgent Care Center location in order to be referred for the treatment at a Baptist Health location.
Monoclonal antibodies are not available at Baptist Health Retail Pharmacies.
Having full vaccination with a COVID-19 vaccine and the appropriate booster helps to increase your protection against COVID-19. For more information about vaccine boosters, click here.